The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study)

Jack L. Martin, Edward T A Fry, Todd Martin, Trevor H. Atherley, Seth S. Martin, Marvin J Slepian

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: We evaluated the early pharmacodynamic profile of the combined 30 mg intravenous and 1 mg/kg subcutaneous enoxaparin loading utilized in the TIMI 11B and ExTRACT TIMI 25 trials. Background: It hasnot been reported whether anti-Xa levels appropriate for percutaneous coronary intervention (PCI) can be reliably achieved within 2 h utilizing this regimen. Methods: Twenty-six patients with acute coronary syndrome (ACS) treated with this regimen had anti-Xa levels measured at 5 min, 2, 4, 6 and 8 h. Results: Seventy-six percent of patients had anti-Xa levels above 0.5 IU/ ml at 5 min. Dose-response curves showed all patients to have anti-Xa levels above 0.5 IU/ml within 1 h. Anti-Xa remained in the targeted range for PCI (0.5 to 1.8 IU/ml) at 2, 4, 6 and 8 h in all patients. Conclusion: This regimen is well suited for ACS treatment with an invasive strategy, including the rapid transition to early and rescue PCI.

Original languageEnglish (US)
Pages (from-to)224-228
Number of pages5
JournalJournal of Thrombosis and Thrombolysis
Volume28
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Enoxaparin
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Therapeutics

Keywords

  • Acute coronary syndromes
  • Anti-Xa levels
  • Early invasive management
  • Low molecular weight heparin

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study). / Martin, Jack L.; Fry, Edward T A; Martin, Todd; Atherley, Trevor H.; Martin, Seth S.; Slepian, Marvin J.

In: Journal of Thrombosis and Thrombolysis, Vol. 28, No. 2, 2009, p. 224-228.

Research output: Contribution to journalArticle

Martin, Jack L. ; Fry, Edward T A ; Martin, Todd ; Atherley, Trevor H. ; Martin, Seth S. ; Slepian, Marvin J. / The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study). In: Journal of Thrombosis and Thrombolysis. 2009 ; Vol. 28, No. 2. pp. 224-228.
@article{4ad6b6b5b182491ea08a8548d2047f4d,
title = "The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study)",
abstract = "Objective: We evaluated the early pharmacodynamic profile of the combined 30 mg intravenous and 1 mg/kg subcutaneous enoxaparin loading utilized in the TIMI 11B and ExTRACT TIMI 25 trials. Background: It hasnot been reported whether anti-Xa levels appropriate for percutaneous coronary intervention (PCI) can be reliably achieved within 2 h utilizing this regimen. Methods: Twenty-six patients with acute coronary syndrome (ACS) treated with this regimen had anti-Xa levels measured at 5 min, 2, 4, 6 and 8 h. Results: Seventy-six percent of patients had anti-Xa levels above 0.5 IU/ ml at 5 min. Dose-response curves showed all patients to have anti-Xa levels above 0.5 IU/ml within 1 h. Anti-Xa remained in the targeted range for PCI (0.5 to 1.8 IU/ml) at 2, 4, 6 and 8 h in all patients. Conclusion: This regimen is well suited for ACS treatment with an invasive strategy, including the rapid transition to early and rescue PCI.",
keywords = "Acute coronary syndromes, Anti-Xa levels, Early invasive management, Low molecular weight heparin",
author = "Martin, {Jack L.} and Fry, {Edward T A} and Todd Martin and Atherley, {Trevor H.} and Martin, {Seth S.} and Slepian, {Marvin J}",
year = "2009",
doi = "10.1007/s11239-009-0326-2",
language = "English (US)",
volume = "28",
pages = "224--228",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study)

AU - Martin, Jack L.

AU - Fry, Edward T A

AU - Martin, Todd

AU - Atherley, Trevor H.

AU - Martin, Seth S.

AU - Slepian, Marvin J

PY - 2009

Y1 - 2009

N2 - Objective: We evaluated the early pharmacodynamic profile of the combined 30 mg intravenous and 1 mg/kg subcutaneous enoxaparin loading utilized in the TIMI 11B and ExTRACT TIMI 25 trials. Background: It hasnot been reported whether anti-Xa levels appropriate for percutaneous coronary intervention (PCI) can be reliably achieved within 2 h utilizing this regimen. Methods: Twenty-six patients with acute coronary syndrome (ACS) treated with this regimen had anti-Xa levels measured at 5 min, 2, 4, 6 and 8 h. Results: Seventy-six percent of patients had anti-Xa levels above 0.5 IU/ ml at 5 min. Dose-response curves showed all patients to have anti-Xa levels above 0.5 IU/ml within 1 h. Anti-Xa remained in the targeted range for PCI (0.5 to 1.8 IU/ml) at 2, 4, 6 and 8 h in all patients. Conclusion: This regimen is well suited for ACS treatment with an invasive strategy, including the rapid transition to early and rescue PCI.

AB - Objective: We evaluated the early pharmacodynamic profile of the combined 30 mg intravenous and 1 mg/kg subcutaneous enoxaparin loading utilized in the TIMI 11B and ExTRACT TIMI 25 trials. Background: It hasnot been reported whether anti-Xa levels appropriate for percutaneous coronary intervention (PCI) can be reliably achieved within 2 h utilizing this regimen. Methods: Twenty-six patients with acute coronary syndrome (ACS) treated with this regimen had anti-Xa levels measured at 5 min, 2, 4, 6 and 8 h. Results: Seventy-six percent of patients had anti-Xa levels above 0.5 IU/ ml at 5 min. Dose-response curves showed all patients to have anti-Xa levels above 0.5 IU/ml within 1 h. Anti-Xa remained in the targeted range for PCI (0.5 to 1.8 IU/ml) at 2, 4, 6 and 8 h in all patients. Conclusion: This regimen is well suited for ACS treatment with an invasive strategy, including the rapid transition to early and rescue PCI.

KW - Acute coronary syndromes

KW - Anti-Xa levels

KW - Early invasive management

KW - Low molecular weight heparin

UR - http://www.scopus.com/inward/record.url?scp=67949109552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67949109552&partnerID=8YFLogxK

U2 - 10.1007/s11239-009-0326-2

DO - 10.1007/s11239-009-0326-2

M3 - Article

C2 - 19291367

AN - SCOPUS:67949109552

VL - 28

SP - 224

EP - 228

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 2

ER -